List view / Grid view
With fluorescence imaging an essential tool in noninvasive biomedical research, the microscopy advancement holds opportunity for progress in optical imaging, according to the paper.
The collaboration between Novartis Pharma AG and Ratio Therapeutics aims to advance a potential best-in-class therapeutic candidate as a treatment for a difficult-to-treat cancer.
This bioproduction investment in Lyon, France supports Sanofi in its goals to lead in the immunology sector.
The new name and logo represent BeiGene’s vision to eliminate cancer through global collaborations to widen its reach for patients.
The acquisition is set to strengthen BioNTech’s capabilities in development and manufacture of next-generation bispecific antibodies.
Results suggest that the small molecule treatment could be an alternative to current medication that aims to prevent HIV infection and which require more frequent dosing.
This investment supports AstraZeneca’s strategy to drive the biopharma company's development in the US.
A key barrier in delivering this type of therapy to patients was overcome in the first-of-a-kind T cell therapy trial, data shows.
The alternative liquid culturing method does not require shaking of microorganisms, according to the research.
Advancement in technology like automation is boosting the adoption of single-use technology rocking bioreactors in the bioprocess market, research says.
With its novel approach for addressing a fundamental cause of eosinophilic esophagitis, approval of the biologic marks a potential new standard of care for paediatric patients.
The Chapter for endotoxin testing using non-animal derived reagents will help quality professionals ensure the safety of sterile pharmaceutical products.
Europe’s emphasis on sustainability combined with its established infrastructure to support market growth, means the region is leading the pharmaceutical containers market, with potential to hold this position into the next decade, research anticipates.
Research and innovation is highlighted in the UK’s Autumn Budget as a priority ‘crucial national asset’ to aid long-term economic growth.
The Itovebi-based combination therapy was recently granted US FDA approval for a common metastatic breast cancer.
